The Comprehensive Guide to Sublingual Ketamine Therapy

What Is Sublingual Ketamine Therapy?

Sublingual ketamine therapy is a treatment approach in which a patient places a compounded ketamine troche (a medicated lozenge) under the tongue, allowing the medication to absorb through the highly vascularized mucosal tissue of the mouth directly into the bloodstream. The word "sublingual" comes from the Latin sub (under) and lingua (tongue), describing the precise anatomical location where absorption is most efficient.

Unlike intravenous (IV) ketamine — which requires a clinic visit, an IV line, and direct medical supervision — sublingual therapy is designed for at-home use under the guidance of a prescribing provider. This format has expanded access to ketamine treatment for patients who cannot afford repeated clinic visits, live far from infusion centers, or prefer the comfort and privacy of home-based care.

The medication itself is the same: racemic ketamine hydrochloride, containing both R-ketamine and S-ketamine enantiomers. What changes is the route of delivery and, consequently, the pharmacokinetic profile — how the drug enters the body, how much reaches the bloodstream, and how quickly effects are felt. Our troche absorption mechanism article explores this pharmacokinetic distinction in depth.

The Science of Sublingual Absorption

Why the Sublingual Route Works

The tissue beneath the tongue is among the thinnest and most richly vascularized mucosal surfaces in the body. The sublingual mucosa lacks the keratinized epithelial layer found on the hard palate and gums, which means molecules can pass through it with relative ease. Small, lipophilic molecules like ketamine are particularly well-suited to sublingual absorption.

When a troche dissolves under the tongue, ketamine molecules diffuse across the mucosal epithelium and enter the dense capillary network just beneath. From there, they pass into the sublingual vein, which drains into the internal jugular vein and directly into systemic circulation — completely bypassing the portal system and the liver's first-pass metabolism.

Bioavailability: What Reaches the Bloodstream

Bioavailability refers to the fraction of an administered dose that reaches systemic circulation in its active form. For ketamine delivered by different routes:

The 25-30% sublingual bioavailability represents a meaningful improvement over simply swallowing the same dose orally. This difference is clinically significant: a 200 mg troche held sublingually delivers roughly 50-60 mg of ketamine to the bloodstream, compared to approximately 34-40 mg if the same dose were swallowed directly.

Factors That Influence Absorption

Several variables affect how much ketamine is actually absorbed sublingually during any given session:

• Dissolution time: Longer contact between the dissolving troche and the mucosal tissue means more absorption. Rushing through dissolution reduces bioavailability.
• Saliva management: Swallowing medicated saliva prematurely sends ketamine to the stomach, where it undergoes first-pass metabolism. Holding saliva in the mouth maximizes mucosal contact.
• Mucosal condition: Dry mouth, oral lesions, recent dental work, or tobacco use can all affect mucosal permeability.
• Troche formulation: The base material, hardness, flavoring agents, and pH of the troche all influence dissolution rate and local drug concentration.
• Fasting status: Eating within 2-4 hours of a session can leave food residue on mucosal surfaces and alter oral pH.

Who Is a Candidate for Sublingual Ketamine Therapy?

Primary Indications

Sublingual ketamine therapy is most commonly prescribed for:

Treatment-resistant depression (TRD): Patients who have failed adequate trials of at least two antidepressant medications. This is the most common indication and the one with the most supporting evidence.

Anxiety disorders: Including generalized anxiety disorder, social anxiety disorder, and health anxiety, particularly when conventional anxiolytics and SSRIs have proven inadequate.

Post-traumatic stress disorder (PTSD): Ketamine's ability to modulate fear circuitry and promote neuroplasticity makes it a promising option for PTSD, especially when combined with trauma-focused psychotherapy.

Chronic pain conditions: Including neuropathic pain, complex regional pain syndrome (CRPS), fibromyalgia, and certain headache disorders. Ketamine's NMDA receptor antagonism addresses central sensitization — the amplification of pain signals by the nervous system.

Suicidal ideation: In patients with acute suicidal thoughts, ketamine has demonstrated rapid antisuicidal effects. This use requires particularly careful provider oversight.

Who Should Not Use Sublingual Ketamine

Contraindications include:

• Uncontrolled hypertension (ketamine temporarily raises blood pressure and heart rate)
• Active psychosis or a history of psychotic disorders (schizophrenia, schizoaffective disorder)
• Current manic episode in bipolar disorder (without mood stabilizer coverage)
• Severe liver disease (ketamine is hepatically metabolized)
• Active substance use disorder involving ketamine or other dissociatives
• Pregnancy or breastfeeding
• Known hypersensitivity to ketamine

A thorough medical evaluation is required before beginning therapy. Our contraindications article provides a detailed breakdown of who should and should not use ketamine.

The Treatment Arc: From Evaluation to Maintenance

Step 1: Evaluation and Screening

Before prescribing ketamine troches, a qualified provider conducts a comprehensive evaluation that typically includes:

• Detailed psychiatric history, including prior medication trials and outcomes
• Medical history with particular attention to cardiovascular, hepatic, and urological health
• Current medication review to identify potential interactions
• Substance use history
• Baseline vital signs (blood pressure, heart rate)
• Informed consent discussion covering risks, benefits, alternatives, and expectations

This evaluation may occur in person or via telehealth, depending on the provider and jurisdiction.

Step 2: Initial Prescription and Pharmacy Coordination

The provider writes a prescription specifying the ketamine dose (commonly 100-200 mg for a starting dose), troche formulation, and frequency. This prescription is sent to a licensed compounding pharmacy, which prepares the troches according to the prescription specifications.

Compounding pharmacies vary in their formulations, turnaround times, and shipping logistics. Most ship directly to the patient via overnight or two-day carriers, as ketamine is a Schedule III controlled substance requiring chain-of-custody documentation.

Step 3: The Acute Loading Phase

The first phase of treatment is designed to build ketamine's therapeutic effects through consistent, frequent dosing:

• Frequency: 2 to 3 sessions per week
• Duration: 4 to 6 weeks (8-18 sessions total)
• Starting dose: Typically 100-200 mg
• Titration: Dose may be adjusted upward in 50 mg increments based on response and tolerability

During this phase, the provider monitors the patient through regular check-ins — often weekly — to assess response, side effects, and technique.

Step 4: Response Assessment

After 4-6 weeks, the provider and patient evaluate treatment response together. Common assessment tools include:

• Patient Health Questionnaire-9 (PHQ-9) for depression
• Generalized Anxiety Disorder-7 (GAD-7) for anxiety
• PTSD Checklist (PCL-5) for trauma symptoms
• Visual Analog Scale (VAS) or Numeric Rating Scale (NRS) for pain
• Patient self-report of functional improvement

A meaningful response is generally defined as a 50% or greater reduction in symptom scores, though any sustained improvement in symptoms and function is clinically relevant.

Step 5: Maintenance Phase

Patients who respond to the acute phase transition to maintenance:

• Frequency: Gradually reduced from twice weekly to once weekly, then biweekly, then monthly
• Dose: May remain the same or be slightly reduced
• Duration: Ongoing, with periodic reassessment

The maintenance schedule is highly individualized. Some patients maintain remission with monthly sessions; others require biweekly dosing indefinitely. The goal is to find the minimum effective frequency that sustains therapeutic gains.

Step 6: Tapering and Discontinuation

If a patient has maintained stable remission for an extended period (typically 6-12 months), the provider may discuss gradual tapering. This involves progressively lengthening the interval between sessions and monitoring for symptom recurrence.

Not all patients can successfully discontinue ketamine therapy. For some, particularly those with refractory conditions, long-term maintenance is the most appropriate approach.

Session Preparation and Environment

Physical Preparation

• Fast for 2-4 hours before the session
• Take prescribed medications as directed (with provider guidance on timing)
• Hydrate well throughout the day; a glass of water 15 minutes before the session helps rinse the oral mucosa
• Avoid caffeine for 1-2 hours and alcohol entirely on session days
• Check blood pressure if your provider requests home monitoring
• Have anti-nausea medication available if prescribed (ondansetron is commonly used)

Environmental Preparation

The setting in which you take a troche significantly affects the quality of your experience:

• Quiet space: Minimize external noise, interruptions, and stimulation
• Comfortable position: A recliner, bed with supportive pillows, or couch where you can remain semi-reclined
• Dim lighting: Bright lights can be uncomfortable during the dissociative phase
• Temperature: A comfortable room temperature with a blanket available
• Eye mask: Many patients find an eye mask helps deepen the internal experience
• Music or silence: Some patients benefit from calming instrumental music; others prefer silence. Discuss with your provider or therapist
• Support person: Ideally, someone is present in the home (not necessarily in the room) who knows you are taking ketamine and can check on you if needed
• Emergency information: Phone charged and accessible; provider's contact information readily available

Mindset Preparation

Approaching each session with intentionality — sometimes called "set" in therapeutic contexts — can enhance outcomes:

• Set a simple intention for the session (what you hope to explore, release, or gain clarity on)
• Release expectations about what the experience "should" feel like
• Practice a few minutes of deep breathing before placing the troche
• Remind yourself that any uncomfortable sensations are temporary and expected

Sublingual Technique: Step by Step

Proper technique directly impacts how much medication reaches your bloodstream and how effective each session is.

1. Wash your hands and remove the troche from its packaging
2. Rinse your mouth with a small amount of plain water — do not use mouthwash or flavored rinse
3. Place the troche under your tongue, as far back in the sublingual space as is comfortable
4. Close your mouth and allow the troche to dissolve naturally — this typically takes 15-30 minutes depending on formulation
5. Do not chew, bite, or actively manipulate the troche with your tongue
6. Allow saliva to pool in your mouth rather than swallowing. The medicated saliva is part of the absorption process
7. After the troche has fully dissolved, continue holding the medicated saliva for an additional 5-10 minutes if tolerable
8. Spit or swallow the remaining saliva according to your provider's instructions. Spitting reduces total ketamine absorption (and therefore side effects); swallowing maximizes it (including the orally-absorbed portion)
9. Recline and rest for 45-60 minutes. Do not attempt to stand, walk, or perform any tasks
10. Remain in your setting until effects have fully subsided — typically 60-90 minutes from placement

What to Expect During a Session

Timeline of Effects

• 0-15 minutes: Bitter taste, gradual numbness of the tongue and mouth. Minimal systemic effects initially.
• 15-30 minutes: Onset of relaxation, possible heaviness in the body, mild perceptual shifts. The troche should be fully dissolved by this point.
• 30-60 minutes: Peak effects. Depending on dose, this may include dissociation (a feeling of detachment from the body or surroundings), altered perception of time, visual phenomena (patterns, colors with eyes closed), emotional surfacing, and deep relaxation.
• 60-90 minutes: Gradual return to baseline. Effects diminish progressively. Cognitive clarity returns.
• 90-120 minutes: Most patients feel functionally normal, though some residual grogginess may persist.

Common Sensations

• Floating or lightness
• Emotional release (tears, laughter, a sense of relief)
• Altered relationship to thoughts — observing them rather than being caught in them
• Mild nausea (more common in early sessions)
• Slight elevation in heart rate or blood pressure
• Tingling or warmth in the extremities

Less Common but Expected Effects

• Vivid mental imagery or dreamlike states at higher doses
• Brief confusion or disorientation during peak effects
• Muscle twitching or involuntary movements
• Temporary difficulty with speech or finding words

Integration: The Work Between Sessions

Integration is the process of making meaning from your ketamine experiences and translating insights into lasting behavioral and emotional change. It is, arguably, the most important component of sublingual ketamine therapy.

Why Integration Matters

Ketamine's antidepressant and anxiolytic effects are partly pharmacological (direct neurochemical effects) and partly experiential (what emerges psychologically during and after sessions). The neuroplastic window that ketamine opens — a period of enhanced synaptic flexibility — creates an opportunity for change, but does not automatically produce it.

Without integration, patients may experience temporary relief that fades between sessions. With intentional integration, the same sessions can catalyze durable shifts in thought patterns, emotional regulation, and behavioral habits. Our integration practices guide offers specific techniques for making the most of this window.

Integration Practices

Journaling: Write about your experience within 1-2 hours of each session while impressions are fresh. Note any emotions, images, thoughts, or physical sensations that stood out. Over time, patterns often emerge.

Psychotherapy: Working with a therapist — particularly one experienced in ketamine-assisted therapy or psychedelic integration — between sessions is strongly recommended. Therapy provides a structured space to process material that surfaces during sessions.

Somatic practices: Yoga, breathwork, gentle movement, or body-based mindfulness can help integrate physical and emotional experiences from sessions.

Lifestyle changes: The neuroplastic window is an opportunity to establish new habits — improved sleep hygiene, regular exercise, social re-engagement, nutritional changes — that support long-term mental health.

Creative expression: Art, music, or other creative outlets can be particularly effective for processing non-verbal or preverbal material.

Managing Side Effects

Nausea

The most common side effect, occurring in 10-20% of patients. Management strategies:

• Fast appropriately before sessions
• Take prescribed anti-nausea medication (ondansetron 4-8 mg) 30 minutes before the troche
• Ginger tea or ginger chews before the session
• Avoid lying completely flat; semi-reclined is better
• Keep a basin nearby for the first few sessions until you know your tolerance

Elevated Blood Pressure

Ketamine causes a temporary increase in blood pressure and heart rate. For most patients, this is mild and self-resolving. If you have hypertension:

• Ensure your blood pressure is well-controlled on your regular medications before starting troche therapy
• Monitor blood pressure before and after sessions if your provider requests it
• Report any readings above 180/110 or symptoms of hypertensive urgency (severe headache, vision changes, chest pain)

Dissociation

Dissociation is not strictly a side effect — it is an expected component of the ketamine experience at therapeutic doses. However, the degree of dissociation varies with dose and individual sensitivity. If dissociation feels overwhelming:

• Grounding techniques: focus on your breath, feel your feet on the floor, hold a textured object
• Reduce the dose at the next session in consultation with your provider
• Ensure your environment is safe and controlled
• Remind yourself that the effects are temporary (typically resolving within 60-90 minutes)

Cognitive Effects

Some patients report "brain fog" or difficulty concentrating for several hours after a session. This is transient and typically resolves by the following day. Do not drive, operate machinery, or make important decisions on session days.

Long-Term Considerations

Tolerance

Some patients develop tolerance over time, requiring higher doses for the same effect. Strategies to mitigate tolerance include:

• Using the minimum effective dose rather than chasing a particular experiential intensity
• Taking scheduled breaks (ketamine holidays) in consultation with your provider
• Rotating session frequency rather than escalating dose

Bladder Health

Long-term, high-dose, or frequent ketamine use has been associated with bladder toxicity (interstitial cystitis) in recreational users consuming far higher doses and frequencies than therapeutic protocols. At therapeutic doses and frequencies, clinically significant bladder issues are uncommon. However:

• Report any urinary symptoms (urgency, frequency, pain, blood in urine) to your provider immediately
• Stay well-hydrated on session days
• Your provider may request periodic urinary assessments for long-term patients

Psychological Dependence

While physical dependence on ketamine at therapeutic doses is rare, psychological reliance — feeling unable to cope without sessions — can develop. This is another reason integration work is so important: building independent coping skills and resilience between sessions prevents the ketamine experience itself from becoming the sole coping mechanism.

Working With Your Provider

Sublingual ketamine therapy is a collaborative process. Effective communication with your prescribing provider is essential:

• Report honestly about your experiences, including challenging or uncomfortable ones
• Track your mood, symptoms, and function between sessions (many providers supply rating scales)
• Discuss any desire to change dose or frequency rather than adjusting on your own
• Report side effects promptly, even if they seem minor
• Attend all scheduled follow-up appointments
• Never share your medication with others — ketamine is a Schedule III controlled substance

What the Research Shows

The evidence base for sublingual ketamine therapy continues to grow. Key findings include:

• Real-world data from at-home troche programs shows response rates of 50-70% for treatment-resistant depression, comparable to IV ketamine in many analyses
• Sublingual ketamine has demonstrated efficacy for anxiety disorders, with improvements often seen earlier in the treatment course than with depression
• For chronic pain, sublingual ketamine provides analgesic benefits that complement but do not replace multimodal pain management
• Long-term safety data from therapeutic-dose protocols is reassuring, with low rates of serious adverse events
• The combination of ketamine therapy with psychotherapy produces more durable outcomes than either intervention alone

Research is ongoing, and the evidence base will continue to mature. Patients should understand that sublingual ketamine troche therapy is an off-label use of an FDA-approved medication — legal and widely practiced, but not specifically FDA-approved for depression, anxiety, or pain in this formulation.

Key Takeaways

• Sublingual ketamine therapy delivers racemic ketamine through the oral mucosa for at-home treatment of depression, anxiety, PTSD, and chronic pain.
• Proper technique — placement, dissolution time, saliva management — directly impacts how much medication reaches the bloodstream.
• Treatment follows an arc: evaluation, acute loading phase (2-3x/week for 4-6 weeks), response assessment, and individualized maintenance.
• Integration practices between sessions are critical for converting ketamine's neuroplastic window into lasting therapeutic change.
• Side effects are generally mild and manageable. Long-term safety at therapeutic doses is supported by growing clinical experience.
• Sublingual therapy is a collaborative relationship between patient and provider — open communication is essential.

References

• Sublingual and Oral Ketamine: A Systematic Review — Analysis of sublingual ketamine bioavailability, clinical outcomes, and pharmacokinetic data across multiple studies
• Ketamine for Treatment-Resistant Depression: Evidence and Mechanisms — Comprehensive review of ketamine's antidepressant mechanisms including NMDA antagonism and synaptogenesis
• NIMH: Ketamine Research — National Institute of Mental Health overview of ongoing ketamine research for mood disorders
• Mayo Clinic: Treatment-Resistant Depression — Overview of treatment-resistant depression and emerging therapeutic approaches
• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications